{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T23:16:05Z","timestamp":1788131765344,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171197"],"award-info":[{"award-number":["82171197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021177","name":"Shenzhen Bay Laboratory","doi-asserted-by":"publisher","award":["21300061"],"award-info":[{"award-number":["21300061"]}],"id":[{"id":"10.13039\/501100021177","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["RCYX20221008092935096"],"award-info":[{"award-number":["RCYX20221008092935096"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Basic and Applied Basic Science Foundation for Distinguished Young Scholars","award":["2023B1515020113"],"award-info":[{"award-number":["2023B1515020113"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86\u00a0million population and faces a significant challenge of Alzheimer\u2019s disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following the standard protocols of the Alzheimer\u2019s Disease Neuroimaging Initiative, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) was initiated in 2021. GHABS participants completed clinical assessments, plasma biomarkers, genotyping, magnetic resonance imaging (MRI), \u03b2-amyloid (A\u03b2) positron emission tomography (PET) imaging, and tau PET imaging. The GHABS cohort focuses on pathophysiology characterization and early AD detection in the Guangdong-Hong Kong-Macao Greater Bay Area. In this study, we analyzed plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      (A), p-Tau\n                      <jats:sub>181<\/jats:sub>\n                      (T), neurofilament light, and GFAP by Simoa in 470 Chinese older adults, and 301, 195, and 70 had MRI, A\u03b2 PET, and tau PET, respectively. Plasma biomarkers, A\u03b2 PET, tau PET, hippocampal volume, and temporal-metaROI cortical thickness were compared between normal control (NC), subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia groups, controlling for age, sex, and\n                      <jats:italic>APOE-\u03b54<\/jats:italic>\n                      . The prevalence of plasma A\/T profiles and A\u03b2 PET positivity were also determined in different diagnostic groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The aims, study design, data collection, and potential applications of GHABS are summarized. SCD individuals had significantly higher plasma p-Tau\n                      <jats:sub>181<\/jats:sub>\n                      and plasma GFAP than the NC individuals. MCI and dementia patients showed more abnormal changes in all the plasma and neuroimaging biomarkers than NC and SCD individuals. The frequencies of plasma A+\/T+ (NC; 5.9%, SCD: 8.2%, MCI: 25.3%, dementia: 64.9%) and A\u03b2 PET positivity (NC: 25.6%, SCD: 22.5%, MCI: 47.7%, dementia: 89.3%) were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The GHABS cohort may provide helpful guidance toward designing standard AD community cohorts in South China. This study, for the first time, reported the pathophysiology characterization of plasma biomarkers, A\u03b2 PET, tau PET, hippocampal atrophy, and AD-signature cortical thinning, as well as the prevalence of A\u03b2 PET positivity in the Guangdong-Hong Kong-Macao Greater Bay Area of China. These findings provide novel insights into understanding the characteristics of abnormal AD pathological changes in South China\u2019s older population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01458-z","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:01:56Z","timestamp":1713243716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pathophysiology characterization of Alzheimer\u2019s disease in South China\u2019s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)"],"prefix":"10.1186","volume":"16","author":[{"given":"Zhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liemin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-0865","authenticated-orcid":false,"given":"Tengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"1458_CR1","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20132412. https:\/\/doi.org\/10.1212\/WNL.43.11.2412-a.","journal-title":"Neurology"},{"key":"1458_CR2","doi-asserted-by":"publisher","unstructured":"Alzheimer Association. 2022 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 2022;18:700\u201389. https:\/\/doi.org\/10.1002\/alz.12638.","DOI":"10.1002\/alz.12638"},{"key":"1458_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000116984","volume":"33","author":"H Braak","year":"1993","unstructured":"Braak H, Braak E, Bohl J. Staging of alzheimer-related cortical destruction. Eur Neurol. 1993;33:403\u20138. https:\/\/doi.org\/10.1159\/000116984.","journal-title":"Eur Neurol"},{"key":"1458_CR4","doi-asserted-by":"publisher","first-page":"e2075","DOI":"10.1212\/WNL.0000000000010596","volume":"95","author":"T Guo","year":"2020","unstructured":"Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Association of CSF A\u03b2, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020;95:e2075\u201385. https:\/\/doi.org\/10.1212\/WNL.0000000000010596.","journal-title":"Neurology"},{"key":"1458_CR5","doi-asserted-by":"publisher","unstructured":"Shi D, Xie S, Li A, Wang Q, Guo H, Han Y, et al. APOE-\u03b54 modulates the association among plasma A\u03b242\/A\u03b240, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults. Transl Psychiatry. 2022;12. https:\/\/doi.org\/10.1038\/s41398-022-01899-w.","DOI":"10.1038\/s41398-022-01899-w"},{"key":"1458_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2967\/jnumed.116.176115","volume":"58","author":"T Guo","year":"2017","unstructured":"Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting Regional Pattern of Longitudinal \u03b2-Amyloid Accumulation by Baseline PET. J Nucl Med. 2017;58:639\u201345. https:\/\/doi.org\/10.2967\/jnumed.116.176115.","journal-title":"J Nucl Med"},{"key":"1458_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jalz.2018.05.013","volume":"14","author":"T Guo","year":"2018","unstructured":"Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of \u03b2-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimer\u2019s Dement. 2018;14:1387\u201396. https:\/\/doi.org\/10.1016\/j.jalz.2018.05.013.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR8","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000207369","volume":"101","author":"J Du","year":"2023","unstructured":"Du J, Li A, Shi D, Chen X, Wang Q, Liu Z, et al. Association of APOE-\u03b54, Osteoarthritis, \u03b2-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory regions in Alzheimer Disease. Neurology. 2023;101:e40\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000207369.","journal-title":"Neurology"},{"key":"1458_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","volume":"12","author":"T Guo","year":"2020","unstructured":"Guo T, Korman D, La Joie R, Shaw LM, Trojanowski JQ, Jagust WJ, et al. Normalization of CSF pTau measurement by A\u03b240 improves its performance as a biomarker of Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:97. https:\/\/doi.org\/10.1186\/s13195-020-00665-8.","journal-title":"Alzheimers Res Ther"},{"key":"1458_CR10","doi-asserted-by":"publisher","unstructured":"Cai Y, Du J, Li A, Zhu Y, Xu L, Sun K et al. Initial levels of \u03b2-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer\u2019s disease. Alzheimers Res Ther 2023:1\u201314. https:\/\/doi.org\/10.1186\/s13195-023-01178-w.","DOI":"10.1186\/s13195-023-01178-w"},{"key":"1458_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ana.26492","volume":"92","author":"G Lan","year":"2022","unstructured":"Lan G, Cai Y, Li A, Liu Z, Ma S, Guo T. Association of Presynaptic Loss with Alzheimer\u2019s Disease and Cognitive decline. Ann Neurol. 2022;92:1001\u201315. https:\/\/doi.org\/10.1002\/ana.26492.","journal-title":"Ann Neurol"},{"key":"1458_CR12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/alz.12890","volume":"19","author":"G Lan","year":"2023","unstructured":"Lan G, Li A, Liu Z, Ma S, Guo T. Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline. Alzheimer\u2019s Dement. 2023;19:2408\u201319. https:\/\/doi.org\/10.1002\/alz.12890.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neurobiolaging.2023.09.012","volume":"132","author":"G Lan","year":"2023","unstructured":"Lan G, Du J, Chen X, Wang Q, Han Y, Guo T. Association of APOE-\u03b54 and GAP-43-related presynaptic loss with \u03b2-amyloid, tau, neurodegeneration, and cognitive decline. Neurobiol Aging. 2023;132:209\u201319. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2023.09.012.","journal-title":"Neurobiol Aging"},{"key":"1458_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","volume":"89","author":"T Guo","year":"2021","unstructured":"Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer\u2019s Disease Pathophysiology. Biol Psychiatry. 2021;89:786\u201394. https:\/\/doi.org\/10.1016\/j.biopsych.2020.06.029.","journal-title":"Biol Psychiatry"},{"key":"1458_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3233\/JAD-230446","volume":"96","author":"A Li","year":"2023","unstructured":"Li A, Du J, Cai Y, Chen X, Sun K, Guo T. Body Mass Index decrease has a Distinct Association with Alzheimer\u2019s Disease Pathophysiology in APOE \u025b4 carriers and non-carriers. J Alzheimer\u2019s Dis. 2023;96:643\u201355. https:\/\/doi.org\/10.3233\/JAD-230446.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1458_CR16","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","volume":"94","author":"T Guo","year":"2020","unstructured":"Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94:e1512\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000009216.","journal-title":"Neurology"},{"key":"1458_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s Disease. N Engl J Med. 2012;367:795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"key":"1458_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17:241\u201350. https:\/\/doi.org\/10.1016\/S1474-4422(18)30028-0.","journal-title":"Lancet Neurol"},{"key":"1458_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain. 2021;144:325\u201339. https:\/\/doi.org\/10.1093\/brain\/awaa399.","journal-title":"Brain"},{"key":"1458_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","volume":"75","author":"RO Roberts","year":"2018","unstructured":"Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a Longitudinal, Population-based setting. JAMA Neurol. 2018;75:970. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0629.","journal-title":"JAMA Neurol"},{"key":"1458_CR22","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS. Association between Elevated Brain Amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305. https:\/\/doi.org\/10.1001\/jama.2017.6669.","journal-title":"JAMA"},{"key":"1458_CR23","doi-asserted-by":"publisher","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 2022:1\u201319. https:\/\/doi.org\/10.1038\/s41591-022-02049-x.","DOI":"10.1038\/s41591-022-02049-x"},{"key":"1458_CR24","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","volume":"5","author":"L Jia","year":"2020","unstructured":"Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Heal. 2020;5:e661\u201371. https:\/\/doi.org\/10.1016\/S2468-2667(20)30185-7.","journal-title":"Lancet Public Heal"},{"key":"1458_CR25","unstructured":"National Bureau of Statistics. The seventh national census of China 2021. http:\/\/www.stats.gov.cn\/zt_18555\/zdtjgz\/zgrkpc\/dqcrkpc\/ggl\/202302\/t20230215_1904001.html (accessed March 1, 2023)."},{"key":"1458_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(19)30290-X","volume":"19","author":"L Jia","year":"2020","unstructured":"Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol. 2020;19:81\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(19)30290-X.","journal-title":"Lancet Neurol"},{"key":"1458_CR27","doi-asserted-by":"publisher","first-page":"e100751","DOI":"10.1136\/gpsych-2022-100751","volume":"35","author":"R Ren","year":"2022","unstructured":"Ren R, Qi J, Lin S, Liu X, Yin P, Wang Z, et al. The China Alzheimer Report 2022. Gen Psychiatry. 2022;35:e100751. https:\/\/doi.org\/10.1136\/gpsych-2022-100751.","journal-title":"Gen Psychiatry"},{"key":"1458_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14283\/jpad.2022.34","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: Appropriate Use recommendations Update. J Prev Alzheimer\u2019s Dis. 2022;8:1\u20132. https:\/\/doi.org\/10.14283\/jpad.2022.34.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1458_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"1458_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"1458_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(19)30368-0.","journal-title":"Lancet Neurol"},{"key":"1458_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of Older people: self-maintaining and instrumental activities of daily Living1. Gerontologist. 1969;9:179\u201386. https:\/\/doi.org\/10.1093\/geront\/9.3_Part_1.179.","journal-title":"Gerontologist"},{"key":"1458_CR33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the Index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914\u20139. https:\/\/doi.org\/10.1001\/jama.1963.03060120024016.","journal-title":"JAMA"},{"key":"1458_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1532-5415.1983.tb03391.x","volume":"31","author":"S Katz","year":"1983","unstructured":"Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc. 1983;31:721\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.1983.tb03391.x.","journal-title":"J Am Geriatr Soc"},{"key":"1458_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cb3e25.","journal-title":"Neurology"},{"key":"1458_CR36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352. https:\/\/doi.org\/10.1016\/j.jalz.2014.01.001.","journal-title":"Alzheimers Dement"},{"key":"1458_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1212\/WNL.59.2.198","volume":"59","author":"DA Bennett","year":"2002","unstructured":"Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198\u2013205. https:\/\/doi.org\/10.1212\/WNL.59.2.198.","journal-title":"Neurology"},{"key":"1458_CR38","unstructured":"Weiner M, Aisen P, Petersen R, Rafii M, Chow T, Shaw LM et al. Alzheimer\u2019s Disease Neuroimaging Initiative 3 (ADNI3) Protocol. 2016;3:1."},{"key":"1458_CR39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Su\u00e1rez-Calvet M, Mont\u00e9 GC, Tucholka A, Falcon C, Rojas S, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2016;12:1259\u201372. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.005.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383. https:\/\/doi.org\/10.1001\/jama.2010.2008.","journal-title":"JAMA"},{"key":"1458_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nucmedbio.2020.03.003","volume":"92","author":"Z Zha","year":"2021","unstructured":"Zha Z, Ploessl K, Choi SR, Alexoff D, Kung HF. Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of \u03b2-amyloid in the brain. Nucl Med Biol. 2021;92:97\u2013106. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.03.003.","journal-title":"Nucl Med Biol"},{"key":"1458_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77:829. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0528.","journal-title":"JAMA Neurol"},{"key":"1458_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2017;13:205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \u03b2-Amyloid change with 18 F-Florbetapir PET and standardized Uptake Value Ratios. J Nucl Med. 2015;56:567\u201374. https:\/\/doi.org\/10.2967\/jnumed.114.148981.","journal-title":"J Nucl Med"},{"key":"1458_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage. 2017;157:448\u201363. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.05.058.","journal-title":"NeuroImage"},{"key":"1458_CR46","doi-asserted-by":"publisher","first-page":"116137","DOI":"10.1016\/j.neuroimage.2019.116137","volume":"202","author":"J-D Tournier","year":"2019","unstructured":"Tournier J-D, Smith R, Raffelt D, Tabbara R, Dhollander T, Pietsch M, et al. MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation. NeuroImage. 2019;202:116137. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116137.","journal-title":"NeuroImage"},{"key":"1458_CR47","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL Neuroimage. 2012;62:782\u201390. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.09.015.","journal-title":"FSL Neuroimage"},{"key":"1458_CR48","doi-asserted-by":"publisher","first-page":"153331752312110","DOI":"10.1177\/15333175231211097","volume":"38","author":"B Weekes","year":"2023","unstructured":"Weekes B, Carthery-Goulart MT. Intervention and Prevention of Dementia in the Greater Bay Area (GBA) of China. Am J Alzheimer\u2019s Dis Other Dementias\u00ae. 2023;38:15333175231211096. https:\/\/doi.org\/10.1177\/15333175231211097.","journal-title":"Am J Alzheimer\u2019s Dis Other Dementias\u00ae"},{"key":"1458_CR49","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3760\/cma.j.issn.0253-9624.2018.09.011","volume":"52","author":"SG Qi","year":"2018","unstructured":"Qi SG, Wang ZH, Wei CB, Yang Z, Zhu XQ. [Case-control study on the influencing factors related to cognitive impairment in the elderly population of China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52:926\u201331. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-9624.2018.09.011.","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"1458_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/alz.12797","volume":"19","author":"MW Weiner","year":"2023","unstructured":"Weiner MW, Veitch DP, Miller MJ, Aisen PS, Albala B, Beckett LA, et al. Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer\u2019s Disease Neuroimaging Initiative 4. Alzheimer\u2019s Dement. 2023;19:307\u201317. https:\/\/doi.org\/10.1002\/alz.12797.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58\u201369. https:\/\/doi.org\/10.1159\/000115751.","journal-title":"Neuroepidemiology"},{"key":"1458_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuroimage.2015.03.069","volume":"144","author":"A Dagley","year":"2017","unstructured":"Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, et al. Harvard Aging Brain Study: dataset and accessibility. NeuroImage. 2017;144:255\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.03.069.","journal-title":"NeuroImage"},{"key":"1458_CR53","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimer\u2019s Dement. 2020;16:750\u20138. https:\/\/doi.org\/10.1002\/alz.12069.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR54","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian imaging, biomarkers and lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease. Int Psychogeriatr. 2009;21:672\u201387. https:\/\/doi.org\/10.1017\/S1041610209009405.","journal-title":"Int Psychogeriatr"},{"key":"1458_CR55","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/alz.12326","volume":"17","author":"C Yang","year":"2021","unstructured":"Yang C, Li X, Zhang J, Chen Y, Li H, Wei D, et al. Early prevention of cognitive impairment in the community population: the Beijing Aging Brain Rejuvenation Initiative. Alzheimer\u2019s Dement. 2021;17:1610\u20138. https:\/\/doi.org\/10.1002\/alz.12326.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR56","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/alz.12700","volume":"19","author":"F Gao","year":"2023","unstructured":"Gao F, Lv X, Dai L, Wang Q, Wang P, Cheng Z, et al. A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer\u2019s dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimer\u2019s Dement. 2023;19:749\u201360. https:\/\/doi.org\/10.1002\/alz.12700.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.26439","volume":"97","author":"H Hu","year":"2022","unstructured":"Hu H, Bi Y-L, Shen X-N, Ma Y-H, Ou Y-N, Zhang W, et al. Application of the amyloid\/tau\/neurodegeneration framework in cognitively intact adults: the CABLE study. Ann Neurol. 2022;97:455\u201368. https:\/\/doi.org\/10.1002\/ana.26439.","journal-title":"Ann Neurol"},{"key":"1458_CR58","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41398-022-02016-7","volume":"12","author":"D-Y Fan","year":"2022","unstructured":"Fan D-Y, Jian J-M, Huang S, Li W-W, Shen Y-Y, Wang Z, et al. Establishment of combined diagnostic models of Alzheimer\u2019s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS). Transl Psychiatry. 2022;12:252. https:\/\/doi.org\/10.1038\/s41398-022-02016-7.","journal-title":"Transl Psychiatry"},{"key":"1458_CR59","doi-asserted-by":"publisher","first-page":"571","DOI":"10.14283\/jpad.2023.49","volume":"10","author":"L Cui","year":"2023","unstructured":"Cui L, Huang L, Pan F-F, Wang Y, Huang Q, Guan Y-H, et al. Chinese preclinical Alzheimer\u2019s Disease Study (C-PAS): design and challenge from PET Acceptance. J Prev Alzheimer\u2019s Dis. 2023;10:571\u201380. https:\/\/doi.org\/10.14283\/jpad.2023.49.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1458_CR60","doi-asserted-by":"publisher","unstructured":"Jia J, Zhao T, Liu Z, Liang Y, Li F, Li Y et al. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ 2023:1\u201311. https:\/\/doi.org\/10.1136\/bmj-2022-072691.","DOI":"10.1136\/bmj-2022-072691"},{"key":"1458_CR61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/alz.12171","volume":"17","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Cui M, Tian W, Zhu S, Chen J, Suo C, et al. Lifestyle, multi-omics features, and preclinical dementia among Chinese: the Taizhou Imaging Study. Alzheimer\u2019s Dement. 2021;17:18\u201328. https:\/\/doi.org\/10.1002\/alz.12171.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR62","doi-asserted-by":"publisher","first-page":"e028188","DOI":"10.1136\/bmjopen-2018-028188","volume":"9","author":"X Li","year":"2019","unstructured":"Li X, Wang X, Su L, Hu X, Han Y. Sino longitudinal study on Cognitive decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open. 2019;9:e028188. https:\/\/doi.org\/10.1136\/bmjopen-2018-028188.","journal-title":"BMJ Open"},{"key":"1458_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36922\/an.v1i1.2","volume":"1","author":"T-R Li","year":"2022","unstructured":"Li T-R, Han Y, Pre -AD. Alliance of China. Insights on amyloid-related imaging abnormalities from the Pre-alzheimer\u2019s disease Alliance of China. Adv Neurol. 2022;1:1\u20139. https:\/\/doi.org\/10.36922\/an.v1i1.2.","journal-title":"Adv Neurol"},{"key":"1458_CR64","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3233\/JAD-215452","volume":"87","author":"C Sheng","year":"2022","unstructured":"Sheng C, Yang K, He B, Li T, Wang X, Du W, et al. Cross-cultural longitudinal study on Cognitive decline (CLoCODE) for subjective cognitive decline in China and Germany: a protocol for Study Design. J Alzheimer\u2019s Dis. 2022;87:1319\u201333. https:\/\/doi.org\/10.3233\/JAD-215452.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1458_CR65","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"key":"1458_CR66","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"key":"1458_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354. https:\/\/doi.org\/10.1038\/nature25456.","journal-title":"Nature"},{"key":"1458_CR68","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"key":"1458_CR69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative disorders. JAMA. 2020;324:772. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"key":"1458_CR70","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"key":"1458_CR71","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78:1471. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"},{"key":"1458_CR72","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1002\/mp.13603","volume":"46","author":"X Zhang","year":"2019","unstructured":"Zhang X, Xie S, Yang J, Weng F, Xu J, Huang Q, et al. A depth encoding PET detector using four-crystals-to-one-SiPM coupling and light-sharing window method. Med Phys. 2019;46:3385\u201398. https:\/\/doi.org\/10.1002\/mp.13603.","journal-title":"Med Phys"},{"key":"1458_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10366-z","author":"K He","year":"2023","unstructured":"He K, Li B, Huang L, Zhao J, Hua F, Wang T, et al. Positive rate and quantification of amyloid pathology with [18F]florbetapir in the urban Chinese population. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-10366-z.","journal-title":"Eur Radiol"},{"key":"1458_CR74","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a Meta-analysis. JAMA. 2015;313:1939\u201350.","journal-title":"JAMA"},{"key":"1458_CR75","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid Pathology in persons without Dementia: a Meta-analysis. JAMA. 2015;313:1924\u201338. https:\/\/doi.org\/10.1001\/jama.2015.4668.","journal-title":"JAMA"},{"key":"1458_CR76","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022;79:228\u201343.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01458-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01458-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01458-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:08:01Z","timestamp":1713244081000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01458-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01458-z","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the GHABS participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}